Q1 2025 Heron Therapeutics Inc Earnings Call Transcript
Key Points
- Heron Therapeutics Inc (HRTX) achieved total net revenues of approximately $39 million in Q1 2025, with a record quarterly adjusted EBITDA of $6.2 million and net income of $2.6 million.
- The oncology franchise, including CINVANTI and SUSTOL, generated combined net revenues of $28.6 million, maintaining market share in a competitive environment.
- ZYNRELEF and APONVIE experienced significant growth in Q1 2025, with increases of over 432% and 60% respectively compared to the same period last year.
- The company reached a settlement agreement with Mylan Pharmaceuticals, avoiding costly litigation fees and removing uncertainty around the outcome of the litigation.
- Heron Therapeutics Inc (HRTX) reported a product gross profit margin of 78% for Q1 2025, an increase from 76% in the same period in 2024, due to production efficiencies.
- Despite revenue growth, the company faces challenges in sustaining and expanding market share for its products in a highly competitive environment.
- The onboarding process for new accounts, particularly for ZYNRELEF, is time-consuming, which may delay the realization of expected sales momentum.
- The company anticipates potential fluctuations in gross profit margins due to varying production scales and costs.
- Heron Therapeutics Inc (HRTX) is still in the process of integrating its CrossLink partnership, which is crucial for optimizing sales efforts and expanding product reach.
- The company is planning targeted expansions in certain areas, which may require additional resources and could impact operational efficiency if not managed carefully.
Good day and thank you for standing by. Welcome to the Heron Therapeutics' Q1 2025 conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Melissa Jarel, Executive Director of Legal at Heron.
Thank you, operator, and good morning, everyone. Thank you for joining us on the Heron Therapeutics' conference call this morning to discuss the company's financial results for the quarter ended March 31, 2025.
With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy & Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
